Certification validates Swisslog Healthcare's dedication to protecting sensitive data and meeting rigorous industry standards Swisslog Healthcar...
Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved LEQEMBI® (lecanemab), a humanized...
Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced th...
Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial...
Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co.,...
Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S....
- AVITA Medical, Inc., a leading therapeutic acute wound care company,announced it has received the CE Mark under the European Union Medical Device Regul...
Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154...
Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnosti...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA ...
NurExone Biologic Inc. , a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the United S...
Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, announced the availability of Pinnacle 21 Enterprise Plus. The solution enables clinical ...
Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has approved HERNEXEOS® (zongertinib tablets)...
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KA...
© 2025 Biopharma Boardroom. All Rights Reserved.
